While our study is the first to exclusively analyze FLT3-ITD mutated patients, others already suggested improved outcomes in FLT3-TKD mutated AML patients, either alone or when co-mutated NPM1 was present [6,40], but this was not consistent across all reports [7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.